Cargando…

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality

AIMS: Use of implantable cardioverter‐defibrillators (ICD) for primary prevention of sudden cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We aimed to investigate barriers to ICD use in HFrEF while considering the predicted risk of mortality and SCD. METHOD A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrage, Benedikt, Lund, Lars H., Benson, Lina, Dahlström, Ulf, Shadman, Ramin, Linde, Cecilia, Braunschweig, Frieder, Levy, Wayne C., Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Cardiac Devices
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545916/ https://www.ncbi.nlm.nih.gov/pubmed/35502681 http://dx.doi.org/10.1002/ejhf.2530

Ejemplares similares

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Diagnosis and management of subcutaneous implantable cardioverter‐defibrillator infections based on process mapping
por: Baddour, Larry M., et al.
Publicado: (2020)

Remote monitoring of implantable cardioverter defibrillators: Patient experiences and preferences for follow‐up
por: Timmermans, Ivy, et al.
Publicado: (2019)

Impact of the COVID‐19 lockdown on the arrhythmic burden of patients with implantable cardioverter‐defibrillators
por: Sassone, Biagio, et al.
Publicado: (2021)

Long-Term Follow-Up of Patients with Chronic Chagas Disease and Implantable Cardioverter-Defibrillator
por: Pereira, Francisca Tatiana Moreira, et al.
Publicado: (2014)

Healthcare utilization in patients with first‐time implantable cardioverter defibrillators (data from the WEBCARE study)
por: Broers, Eva R., et al.
Publicado: (2019)

Long‐term follow‐up of implantable cardioverter defibrillator patients with regard to appropriate therapy, complications, and mortality
por: Mattsson, Gustav, et al.
Publicado: (2020)

Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter‐Defibrillator Generator Changes
por: Bilchick, Kenneth C., et al.
Publicado: (2022)

Association between implantable cardioverter-defibrillator and survival in patients awaiting heart transplantation: A meta-analysis and systematic review
por: Lin, Andrew Y., et al.
Publicado: (2021)

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Implantable cardioverter-defibrillator–related procedures and associated complications in continuous flow left ventricular assist device recipients: A multicenter experience
por: Ravichandran, Ashwin, et al.
Publicado: (2021)

Renal function and the long‐term clinical outcomes of cardiac resynchronization therapy with or without defibrillation
por: Leyva, Francisco, et al.
Publicado: (2019)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Pulmonary artery pressure‐guided heart failure management: US cost‐effectiveness analyses using the results of the CHAMPION clinical trial
por: Martinson, Melissa, et al.
Publicado: (2016)

The cost‐effectiveness of real‐time pulmonary artery pressure monitoring in heart failure patients: a European perspective
por: Cowie, Martin R., et al.
Publicado: (2017)

Assessment of Association Between Venous Occlusion and Infection of Cardiac Implantable Electronic Devices
por: Keyser, Andreas, et al.
Publicado: (2021)

Subcutaneous implantable cardioverter-defibrillator generator removal: a multicenter analysis
por: Luker, J, et al.
Publicado: (2023)

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience
por: Kutyifa, Valentina, et al.
Publicado: (2014)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Who Benefits From a Defibrillator—Balancing the Risk of Sudden Versus Non-sudden Death
por: Beggs, Simon A. S., et al.
Publicado: (2018)

Appropriate therapy for implantable cardioverter defibrillators used as primary versus secondary prophylaxis
por: Thuraiaiyah, J, et al.
Publicado: (2023)

Pulsed-field ablation in patients with permanent pacemaker or implantable cardioverter defibrillator: Is it safe?
por: Lennerz, C, et al.
Publicado: (2023)

Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator
por: Wan, Chingping, et al.
Publicado: (2013)

Remote monitoring of implantable cardioverter-defibrillators and resynchronization devices to improve patient outcomes: dead end or way ahead?
por: Braunschweig, Frieder, et al.
Publicado: (2019)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
por: Coats, Andrew J.S., et al.
Publicado: (2022)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Pacemaker and Defibrillator Implantation and Programming in Patients with Deep Brain Stimulation
por: Elliott, Mark, et al.
Publicado: (2019)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest
por: Lakshmanadoss, Umashankar, et al.
Publicado: (2011)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Eustachian and Tricuspid Valve Endocarditis: A Rare Consequence of the Automatic Implantable Cardioverter-Defibrillator Placement
por: Rawal, Harsh, et al.
Publicado: (2021)

Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death
por: Wäßnig, Nadine K., et al.
Publicado: (2016)

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator
por: Skowasch, Dirk, et al.
Publicado: (2018)

Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
por: Kutyifa, Valentina, et al.
Publicado: (2018)

Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review
por: Borne, Ryan T., et al.
Publicado: (2017)

Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis
por: Nguyen, Elaine, et al.
Publicado: (2018)

Use of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in Asia
por: Ueda, Nobuhiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_04ka4ordkln9jj1bcf9j6n6ees